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Nuclear bodiesThe human cytomegalovirus (HCMV) UL35 gene encodes two proteins, UL35 and UL35a. Expression of UL35
in transfected cells results in the formation of UL35 nuclear bodies that associate with promyelocytic leukemia
(PML) protein. PML forms the basis for PML nuclear bodies that are important for suppressing viral lytic gene
expression. Given the important relationship between PML and viral infection, we have further investigated
the association of UL35 with PML bodies. We demonstrate that UL35 bodies form independently of PML and
subsequently recruit PML, Sp100 and Daxx. In contrast, UL35a did not form bodies; however, it could bind
UL35 and inhibit the formation of UL35 bodies. The HCMV tegument protein pp71 promoted the formation of
UL35 bodies and the cytoplasmic localization of UL35a. Similarly, UL35a shifted pp71 to the cytoplasm. These
results indicate that the interplay between UL35, UL35a and pp71 affects their subcellular localization and
likely their functions throughout infection.r).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Human cytomegalovirus (HCMV) is a member of the beta herpes-
virus subfamily and can establish both lytic and life-long latent
infections in human hosts. In most healthy adults, HCMV infections
are mild or asymptomatic. However, lytic HCMV replication can cause
serious complications and even death in immunocompromised hosts,
such as transplant recipients, people with AIDS and neonates (Crough
and Khanna, 2009). Lytic replication involves the controlled and
coordinated expression of viral genes generally divided into the
immediate early (IE), early (E) and late (L) phases. In addition to this,
pre-formed viral proteins contained within the tegument layer of the
virion are delivered to newly infected cells and can modify the cellular
environment and contribute to the initiation of IE gene expression
during a pre-IE phase of the replication cycle (Kalejta, 2008). The major
immediate early promoter (MIEP) controls the expression of the
immediate early gene products, IE1 and IE2, which in turn coordinate
the expression of early and late genes and drive the progression of lytic
replication (Reeves, 2010; Sinclair and Sissons, 2006). Expression from
the MIEP is complex with both viral and cellular factors regulating its
activation and repression during latency and various stages of lytic
replication (Kalejta, 2008; Sinclair, 2010). During initial infections,
components of the virion tegument facilitate activation of the MIEPpromoter (Kalejta, 2008). Themost important and best characterized of
these is the tegument protein pp71 (UL82) (Cantrell and Bresnahan,
2005; Saffert and Kalejta, 2006). In addition, two other tegument
proteins, UL69 andUL35, have the ability to activate theMIEP in reporter
assays and may behave similarly during infection (Liu and Biegalke,
2002; Winkler et al., 2000).
In order to suppress lytic infection, the host cell can inhibit viral gene
expression through promyelocytic leukemia (PML) nuclear bodies
(NBs). PML-NBs are dynamic, spherical, multi-protein nuclear com-
plexes that require thePMLprotein for formation (Bernardi andPandolﬁ,
2007). PML-NBs are involved in regulating a host of nuclear activities
including apoptosis, gene expression, DNA repair and senescence
(Bernardi and Pandolﬁ, 2007; Dellaire and Bazett-Jones, 2004). In
addition, PML and the PML body components Sp100 and Daxx form part
of an intrinsic and interferon-inducible antiviral response (Everett et al.,
2006; Saffert and Kalejta, 2006; Tavalai et al., 2006). For herpes simplex
virus-1 (HSV) and HCMV, the basis of this response is the silencing of
viral IE gene expression through associationwith PMLbody components
and the ability of these components (e.g., Daxx, ATRX, Sp100) to affect
transcriptional regulation (Everett et al., 2006; Lukashchuk and Everett,
2010; Lukashchuk et al., 2008; Negorev et al., 2006; Saffert and Kalejta,
2006; Woodhall et al., 2006). For HSV infections, PML, Sp100 and Daxx
become associatedwith viral genomes soon after delivery to the nucleus
and, in the absence of the tegument protein ICP0, this association
suppresses lytic replication (Everett and Murray, 2005; Everett et al.,
2006). ICP0 also localizes to PML-associated genomeswhere it promotes
the degradation of PML and Sp100, resulting in the disruption of PML-
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Maul, 1994). Similar to HSV, incoming HCMV genomes become
associated with PML early after infection, resulting in repression of the
strong CMV IE promotor, possibly through histone modiﬁcation of the
MIEP promoter region (Ishov et al., 1997; Nitzsche et al., 2008; Reeves,
2010; Woodhall et al., 2006).
In order to counter the repressive effects of PML-NBs, HCMV encodes
several proteins that have the ability to alter and disrupt PML NBs or the
PML NB components that repress immediate early gene expression (Ahn
and Hayward, 2000; Saffert and Kalejta, 2006; Salsman et al., 2008). The
tegument protein pp71 plays an important part in this process by
countering the repressive effects of Daxx and ATRX on theMIEP (Cantrell
andBresnahan, 2006; Lukashchuket al., 2008;PrestonandNicholl, 2006).
These effects are dependent on the interaction between Daxx and pp71,
which facilitates the displacement of ATRX from genome-associated PML
bodies, themodiﬁcationofDaxxbySUMOand thedegradationofDaxxby
the proteasome (Hofmann et al., 2002; Hwang and Kalejta, 2007; Hwang
and Kalejta, 2009; Lukashchuk et al., 2008; Saffert and Kalejta, 2006).
Activation of theMIEP results in expression of IE1, which also localizes to
PML-associated genomes and causes de-sumoylation of PML and
dispersion of PML NBs, allowing for more efﬁcient expression from the
MIEP and replication to proceed (Ahn and Hayward, 1997; Ahn and
Hayward, 2000; Korioth et al., 1996). In addition to pp71 and IE1, UL35
also associates with PML and pp71 appears to enhance this association
(Schierling et al., 2004). Furthermore, UL35 acts cooperatively with pp71
to activate expression from theMIEP in reporter assays (Liu and Biegalke,
2002; Schierling et al., 2004), suggesting that UL35 might contribute to
relieving PML-mediated repression of the MIEP.
The HCMV UL35 gene encodes two proteins, UL35 and UL35a, which
areexpressedatdifferent timesduring infection (Liu andBiegalke, 2002).
The640amino acids—longUL35 is produced late in infection, is packaged
into progeny virions as a minor tegument component (Varnum et al.,
2004), and is thus delivered pre-formed to newly infected cells. UL35a,
which consists of amino acids 448–640 of UL35, is transcribed from a
separate promoter and expressed during both the early and late phases
of infection (Liu andBiegalke, 2002). UnlikeUL35, UL35adoes not appear
to be packaged in the tegument of the virion (Liu and Biegalke, 2002;
Varnum et al., 2004). In addition, UL35a can antagonize pp71-mediated
activation of the MIEP, whereas UL35 enhances pp71-mediated MIEP
activation (Liu andBiegalke, 2002; Schierling et al., 2004). Deletion of the
UL35 gene results in loss of both UL35 and UL35a, and studies with the
mutant virus demonstrate that the UL35 gene is essential at lowMOI and
results in delayed replication and some growth defects at higher MOI
(Dunn et al., 2003; Schierling et al., 2005).
Given the importance of PML NBs for controlling viral replication, we
have previously conducted a screen for viral proteins that alter or disrupt
PML NBs (Salsman et al., 2008). Ninety-three proteins from HSV, HCMV
andEBVwereexamined for their effectsonPMLNBs, identifyingnineteen
proteins that induce loss of the NBs and ﬁve proteins that localized with
and altered PML NBs. UL35 was identiﬁed in the latter category and was
observed to form ring-like structures that contained PML. Here we
further explore the nature of these UL35 bodies, their association with
PML and how the interplay between UL35, UL35a and pp71 affects these
bodies as well as each protein's subcellular localization.
Results
HCMV UL35 forms nuclear bodies
Various localizations of UL35 have been reported in the literature
including pan-nuclear localization of untagged UL35 (Schierling et al.,
2004), nuclear with nuclear body (NB) localization for SPA-tagged UL35
(Salsman et al., 2008) and cytoplasmic localization for GFP-tagged UL35
(LiuandBiegalke, 2002). Tohelp clarify thesediscrepancies,wegenerated
plasmids that express UL35 with either no epitope tag (UL35-wt), a C-
terminal triple FLAG tag (UL35-F) or a C-terminal sequential peptideafﬁnity (SPA) tag (Zeghouf et al., 2004) consisting of a calmodulinbinding
peptide and a triple FLAG epitope tag (UL35-S). We also generated
plasmids that express UL35a, the truncated form of UL35, with either no
epitope tag (UL35a-wt), a FLAG tag (UL35a-F) or a SPA tag (UL35a-S).
Western blots of cell lysates expressing these constructs conﬁrmed their
expected size and epitope tags and showed that all the UL35 and UL35a
proteins reacted with the UL35 antiserum (Fig. 1A). Importantly, no
UL35a sized bands were detected in UL35-transfected cell lysates, and
therefore, the subcellular localizations seen in UL35-transfected cells
represent differently localized UL35 and not a combination of UL35 and
UL35a localizations.
By immunoﬂuorescence, all three UL35 constructs displayed similar
localization patterns and were primarily nuclear localized (~70%) with
about 30% of cells showing both nuclear and cytoplasmic localization
(Fig. 1B). Consistent with our previous results, in many of the UL35-S
transfected cells, UL35 also formed several subnuclear dots and/or
donut shaped structures that were clearly detected using the FLAG
antibody (Fig. 1B). UL35-F and UL35-wt also formed subnuclear bodies
in transfected cells in addition to nucleoplasmic staining (Fig. 1B). We
quantiﬁed the percentage of UL35-transfected cells that contained NBs
and found that UL35-wt and UL35-F formed NBs in ~50% of transfected
cells, while UL35-S formed NBs in ~70% of transfected cells (Fig. 1C). In
addition, although there is a big range in the number of NBs per cell for
all UL35 construct, the average number of NBs per cell was similar for all
UL35 constructs; namely 7.4 for UL35-S, 6.4 for UL35-F and 6.7 for UL35-
wt (see Figs. 2D and 7E). However, we noticed that for both UL35-S and
UL35-F, the UL35 NBs were more clearly detected using the FLAG
antibody than with the UL35 antiserum (Fig. 1D), suggesting that the
UL35 epitope recognized by this antiserum is not as accessible as the C-
terminal tag in the context of UL35 NBs.
In addition to forming symmetrical dot or donut structures, UL35
was also found associated with irregularly shaped nucleolar-like
structures (Fig. 1D, asterisks). The association of a proportion of UL35
with the nucleolus was conﬁrmed by co-staining for UL35 and the
nucleolar protein EBP2 (EBNA1 binding protein 2; Nayyar et al 2009)
(Supplemental Figure 1). Notably, the dot/donut shapedUL35NBswere
not associated with EBP2 (Supplemental Figure 1, arrows) indicating
that these structures are distinct from the nucleolar localization. Only
these non-nucleolar structures are referred to here as UL35 NBs.
The localization of UL35awas also examined and found to benuclear
in ~70% of transfected cells. Like UL35, a small proportion of UL35a
showed nucleolar localization (Fig. 1E asterisks and Supplemental
Figure 1). However, unlike UL35, NBswere not observedwith UL35a for
any of the three constructs with the FLAG or UL35 antibodies (Fig. 1B
and E). These results indicate that, although UL35 and UL35a are both
primarily nuclear, UL35, but not UL35a, can form nuclear bodies in the
absence of other viral proteins.
UL35 nuclear bodies associate with and remodel PML bodies
We next explored the relationship between the UL35 NBs and PML,
ﬁrst by expressing UL35with andwithout epitope tags in U2OS cells. In
the absence of UL35, PML NBs are seen as several small punctate foci
within the nucleus (Fig. 2A, top row). In cells expressing UL35, PML
strongly colocalized with UL35 NBs regardless of the presence or
absence of an epitope tag (Fig. 2A). In addition, this colocalization with
UL35 NBs resulted in a reorganization of PMLNBs from several punctate
bodies to crescent- and ring-shaped bodies that co-localize with the
surface of theUL35NB. Inmost cells, all of thevisible PMLwasassociated
with UL35 NBs, however, occasionally UL35 NBs were observed that
werenot associatedwithPML(Fig. 2A, arrow). In contrast, UL35a,which
does not form NBs, did not associate with cellular PML and did not
appear to alter the number or morphology of PML NBs (Fig. 2B).
Herpesvirus proteins can disrupt PML NBs by various mechanisms
includingpromoting the degradation of PMLproteins, as seen for ICP0 of
HSV andEBNA1of Epstein–Barr virus (Everett et al., 1998; Sivachandran
Fig. 1. UL35 forms nuclear bodies. (A) U2OS cells were transfected with different UL35 and UL35a expression plasmids as indicated and 48 h post-transfection cell lysates were analyzed by
Western blotting. UL35 and UL35a were detected with anti-FLAG antibody or UL35 antiserum as indicated. (B) U2OS cells were transfected with the indicated UL35 and UL35a expression
plasmids and, 48 h later, the localization of these proteins (green) was determined by immunoﬂuorescence microscopy using anti-FLAG (UL35-F and UL35-S) or anti-UL35 (UL35-wt and
UL35a-wt) antibodies. DAPI stains (blue) are also shown. (C) U2OS cells were transfectedwith UL35-S, UL35-F or UL35-wt and the percentage of UL35-expressing cells that contained nuclear
bodies at 48 hpost transfectionwasdeterminedby immunoﬂuorescencemicroscopyas in (D).Values represent themean±s.e.,n=4–6. (D)Examplesof cells quantiﬁed in (C) inwhichUL35-F
and UL35-S were detected with anti-FLAG antibody (green) and UL35-wt was detected with anti-UL35 antibody (red). Arrows indicate an example of UL35 NBs for each image. Asterisks in
merged images indicate an exampleof nucleolar staining. (E)U2OScells expressingUL35awithandwithout the indicated tagswere imagedusinganti-FLAG(green)or anti-UL35 (red)primary
antibodies. Asterisks indicate an example of nucleolar staining.
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levels of PML proteins, UL35- and UL35a-transfected U2OS cell lysates
were analyzed by PML immunoblot. Neither UL35 nor UL35a affected the
overall levels of PML, despite the fact that they were expressed at highlevels in over 80% of the cells (Fig. 2C). We next determined if UL35 or
UL35a affected the ability of PML to form bodies by counting the PML
bodies in control andUL35- andUL35a-transfected cellswithandwithout
an epitope tag (Fig. 2D and E). Control cells had an average of 11.2±0.6
Fig. 2.UL35 associateswith and alters PMLbodies. (A) Representative images of single nuclei fromuntransfected (top row) andUL35-S, UL35-F orUL35-wt transfected cells immunostained for
PML (red) and UL35 (green) using anti-FLAG (UL35-S and UL35-F) or UL35 antiserum (UL35-wt). Arrow indicates a UL35 NB not associatedwith PML. (B) A representative image of a UL35a-
transfected U2OS cell immunostained for UL35a and PML as indicated. (C) Western blot analysis for PML, actin and FLAG of cell lysates from U2OS cells expressing UL35-S or UL35a-S. The
multiple bands in the PML blot represent the different isoforms of PML. (D) The average number of PML bodies (red bars) or UL35 NBs (green bar) was determined by immunoﬂuorescence
microscopy for U2OS cells expressing UL35-S or UL35a-S as indicated. The values represent the mean±s.e. (n=3–5). (E) The same experiment as D, except that cells were transfected with
untagged UL35 and UL35a. Values represent the mean±s.e. (n=3–4).
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S, Fig. 2D) and 10.8±0.9 (UL35a-wt, Fig. 2E) PML bodies per cell. In
contrast, UL35-S andUL35-wt-transfected cells had somewhat fewer PML
bodies (8.7±0.7, and 9.6±0.2, respectively) than control cells (Fig. 2D
and E). Interestingly, the average number of UL35NBs per transfected cell
was determined to be 7.4±0.4 (UL35-S, Fig. 2E) and 7.6±0.3 (UL35-wt,
Fig. 2E). Given that most of the visible PML is associated with UL35 NBs
(and vice versa) (Fig. 2A) it stands to reason that the average number of
PML bodies would approach the average number of UL35 NBs. Thus,
althoughUL35doesnot appear to signiﬁcantly inhibit the ability of PML to
formbodies, the association of PMLwithUL35 can cause a slight reduction
in average PML body number.
Since we have shown that UL35 can alter PML localization, we
investigated whether other components of PML NBs were alsorelocalized. In particular, we examined Sp100 and Daxx because they
are commonPMLbody components that are involved in the repression of
viral gene expression and are targets of other herpesvirus proteins
(Everett et al., 2006; Negorev et al., 2006; Saffert and Kalejta, 2006). We
found that Sp100andDaxxboth colocalizedwithUL35NBs anddisplayed
the same typeof reorganization as PML (Fig. 3). These results indicate that
UL35 not only affects PML proteins, but induces remodeling of PML NBs.
UL35 NBs form independently of PML
Next, we wanted to distinguish between two possible explanations
for the association between UL35 and PML. In one model, UL35 NBs
represent theaccumulationofUL35at existingPMLbodies. Alternatively,
UL35 might form NBs independently of PML and, once assembled, these
Fig. 4. UL35 NBs form independently of PML. (A) U2OS cells were transfected with
UL35-F and immunostained for PML (red) and UL35 (green) at 5 h post-transfection.
Examples of UL35 NBs that are not associated with PML are indicated with arrows.
(B) Immunoﬂuorescent images of U2OS cells with shRNA-silenced PML, 40 h after
transfection with plasmids expressing UL35-F and UL35-wt. Arrows point to examples
of UL35 NBs. (C) Quantiﬁcation of UL35 NBs in shPML-U2OS cells. Cells were transfected
with UL35-F or UL35-wt, ﬁxed and immunostained at 40 h post-transfection and the
percentage of transfected cells containing UL35 NBs was determined. Values represent
the mean ± s.e. (n =3–4).
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PML body component. The later possibility is supported by the above
observations that not all UL35 NBs contain detectable PML. Two
approaches were employed in order to distinguish between these
possibilities. First, UL35-F transfected cellswereﬁxed at early times post-
transfection and analyzed for UL35 NB formation and the association of
those NBs with PML bodies. In U2OS cells expressing UL35-F, the
distribution of UL35 was largely pan-cellular at early times post
transfection, however, UL35 NB formation occurred as early as 4–6 h
post transfection and the UL35 bodies appeared as multiple dot-like
structures (Fig. 4A, arrows). At this early time, cellular PML bodies
appeared normal and were not strongly associated with UL35 NBs
(Fig. 4A). The presence of UL35 NBs that were not associated with PML
bodies indicates that UL35 NBs do not form at preexisting PML bodies.
In order to further test if UL35NB formation occurs independently of
PML, UL35-F or UL35-wt were expressed in U2OS cells in which all PML
isoforms had been silenced with shRNA expressed from a lentivirus, as
previously described (Everett et al., 2006). Both UL35-F and UL35-wt
were able to form NBs in U2OS-shPML cells despite the fact that they
lacked any detectable PML NBs (Fig. 4B). The percentage of transfected
cells with UL35 NBs was determined to be ~50% for both UL35-F and
UL35-wt (Fig. 4C), which is nearly identical to the percentage of cells
with UL35 NBs in the parental cells containing PML (Fig. 1C). These
results demonstrate thatUL35NBs form independently of PMLbodies or
PML protein and indicate that PML protein becomes associated with
UL35 after UL35 NBs are formed.
UL35 and UL35a interact with themselves and with each other
UL35andUL35a appear tohaveopposing activitieswith respect to the
major immediate early promoter (MIEP) and UL35a is present in the cell
when UL35 is expressed late in infection. Therefore, we wanted to
understand more about the interplay between these two proteins. We
began by investigating whether UL35 and UL35a can interact with
themselves or with each other. For these experiments, we generated
plasmids expressing C-terminally myc-tagged UL35 and UL35a (UL35-Fig. 3. Daxx and Sp100 associate with UL35 nuclear bodies. Representative immunoﬂuores-
cence images of CNE-2Z cells transfected with UL35-F (green) and immunostained for PML,
Daxx and Sp100 (red) as indicated. Arrows indicate an example of UL35 NBs co-localizing
with PML, Daxx or Sp100.myc and UL35a-myc, respectively) and used them to co-transfect 293A
cells along with the expression plasmids for either UL35-S or UL35a-S.
FLAG immunoprecipitation of cell lysates containing UL35-myc and
UL35-S recovered both proteins (Fig. 5A), indicating that UL35 can
interact with itself. As expected, in the absence of UL35-S, no UL35-myc
couldbedetected in theelution (Fig. 5A). Similarly,whenUL35a-mycwas
co-expressedwith eitherUL35a-S orUL35-S, FLAG immunoprecipitations
recovered UL35a-myc along with both UL35-S and UL35a-S (Fig. 5B). In
contrast, UL35a-myc was not recovered in the absence of UL35-S or
UL35a-S (Fig. 5B). These results demonstrate that UL35 and UL35a have
the ability to associate with themselves and with each other in cells. In
addition, UL35a-mycwas co-expressedwith the FLAG-taggedN-terminal
region of UL35 (UL35N-F, amino acids 1–447), which does not share
sequencewith UL35a (amino acids 448–640). UL35a-mycwas recovered
with UL35N-F by FLAG immunoprecipitation, indicating that UL35
contains at least two UL35a-interacting motifs; one in the N-terminal
region and one in the C-terminal region.
UL35a inhibits UL35 NB formation
Since UL35 and UL35a can interact and can be expressed at the same
time during infection, we examined the effect of UL35a on UL35 NB
formation. To this end, U2OS cells were co-transfected with UL35-F and
UL35a-myc, and the extent of UL35-NB formation was determined by
immunoﬂuorescence microscopy. When UL35-F was expressed on its
own UL35 was able to form nuclear bodies in ~60% of cells at 24 h post-
transfection (Fig. 6A).WhenUL35a-mycwas co-transfectedwithUL35-F
at an input DNA ratio of 1:9 (UL35:UL35a), many cells expressing both
proteins showed reduced UL35 NB formation (but no obvious reduction
in nucleolar staining, Fig. 6A). In order to quantify this effect, U2OS cells
were transfected with a constant amount of UL35-F DNA and increasing
amounts of UL35a-myc DNA at a 1:0, 1:3 and 1:9 ratio. We then
determined the number of cells with one or more UL35 NBs, for 3
Fig. 5. UL35 and UL35a interact with themselves and with each other. 293A cells were
transfected with UL35-S and/or UL35-myc (A) or with UL35-S, UL35a-S, UL35N-F and/or
UL35a-myc (B) alone or in combination as indicated. FLAG-tagged proteins were
immunoprecipitated from cell lysates (input) and recovered immunoprecipitants
(αFLAG IP) were probed for FLAG- and myc-tagged proteins as indicated.
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of UL35 NBs by UL35a (Fig. 6B). A 9-fold excess of UL35a over UL35
resulted in a signiﬁcant (p=0.001) inhibitionofUL35NB formation such
that about 70% of cells that expressed UL35a had no UL35 NBs (Fig. 6B).
This decrease in UL35 NB formation was not due to a decrease in UL35
expression, since UL35 levels were the same regardless of the amount of
UL35a present (Fig. 6C). These results indicate that UL35a has the ability
to inhibit UL35 NB formation.pp71 enhances UL35 NB formation
In addition to UL35a, the tegument protein pp71 also interacts with
UL35, is expressed with early–late kinetics (Liu and Biegalke, 2002) and
would therefore be expressed late in infectionwhenUL35 is also present.
In order to explore the effects of pp71 on UL35 NB formation, UL35-wt
was co-expressed with HA-tagged pp71. In the presence of pp71, the
formation of UL35 NBs was obviously increased as compared to UL35
expressed on its own and the nucleoplasmic and nucleolar-like staining
of UL35 was reduced (Fig. 7A). These effects were not seen with a
negative control HA-tagged protein (BZLF1 from Epstein–Barr virus;
Supplemental Figure 2). When expressed on its own, UL35-wt formed
NBs in ~50% of cells (Fig. 1D) and, of those cellswith UL35NBs, therewas
an average of 6.7UL35NBsper cell (Fig. 7E). In the presence of pp71, over
99% of UL35-expressing cells containedUL35NBs (Fig. 7D) and therewas
an average of 12.7 UL35 NBs per co-transfected cell (Fig. 7E). Although
partial pp71 localization to UL35NBswas observed in some cells (Fig. 7A,
arrow),most cells did not show a high degree of accumulation of pp71 at
UL35 NBs.We also found that UL35 retains the ability to remodel PML in
the presence of pp71 with PML strongly associated with UL35 NBs
(Fig. 7C). In light of our observations that UL35 NB formation does not
require PML, we testedwhether pp71-mediated UL35 NB formationwas
PML-dependent. U2OS cells with silenced PML were transfected with
either UL35-wt alone or co-transfected with UL35-wt and HA-pp71
(Fig. 7B) and the UL35 NBs were quantiﬁed as above (Fig. 7D and E). The
results in shPML-U2OS cells were indistinguishable from those inparental U2OS cells, indicating that pp71 can increaseUL35NB formation
independently of PML.
UL35a promotes cytoplasmic accumulation of pp71
Since pp71 can also interact with UL35a and both proteins are
expressed with UL35 late in infection, we examined what effects UL35a
and pp71 had on each other. In U2OS cells, both pp71-HA andUL35a-wt
display primarily nuclear localization (Fig. 8A and B). When pp71 and
UL35a were expressed together the localization of both UL35a and pp71
wasobviouslydifferentwithpp71becomingpredominantly cytoplasmic
and UL35a showing increased cytoplasmic localization in addition to its
nuclear localization (Fig. 8C and D). In addition, many co-transfected
cells contained several dot-like structures in the cytoplasm that
contained both UL35a and pp71 (Fig. 8C).We quantiﬁed the localization
of pp71 and UL35a alone or together and determined that when
expressed alone, UL35a and pp71 showed nuclear localization in about
75% of all transfected cells (Fig. 8B). About 20%–25% of pp71 or UL35a
expressing cells had both nuclear and cytoplasmic (i.e. pancellular)
localization, while 0%–5% of cells were predominantly cytoplasmic
(Fig. 8B). When expressed together UL35a caused a dramatic shift in the
distribution of pp71 from nuclear to cytoplasmic with ~75% of
transfected cells containing predominantly cytoplasmic pp71 and ~25%
of cells showing pancellular distribution of pp71 (Fig. 8D). Virtually no
cells contained strictly nuclear-localized pp71 in the presence of UL35a.
The localization of UL35a was also affected by pp71 with a pancellular
distribution becoming predominant (~60%) and nuclear or cytoplasmic
localizations each comprising about 20% of co-transfected cells (Fig. 8D).
These results demonstrate that UL35a and pp71 can inﬂuence each
other's subcellular localization.
Discussion
We have examined the subcellular localization of UL35, UL35a and
pp71 and how these proteins affect the localization of each other. The
reported localization pattern of UL35 is variedwith cytoplasmic (Liu and
Biegalke, 2002), nuclear (Schierling et al., 2004) and sub-nuclear
(Salsman et al., 2008) patterns having been described. Based on these
studies andour current results, two factorsmay contribute to thevariable
results thathavebeen reported. First, thepresenceof aC-terminal tag (i.e.
GFP, SPA, FLAG) appears to inﬂuence the subcellular localization of UL35,
shifting the balance between NBs and nucleoplasmic localization and, in
the case of the EGFP tag used by Liu and Biegalke (2002), may have
induced the cytoplasmic localization of UL35 that they observed. The
second factor that likely contributed to the reported differences in UL35
localization is the speciﬁcity of the polyclonal antibody directed against
UL35 (Liu and Biegalke, 2002). Our results show that this antibody is
more sensitive fornucleoplasmicUL35 than forUL35NBs,most likelydue
to the masking of epitopes when UL35 is assembled in NBs.
Despite the differences in UL35 NB detection, it is clear that both
tagged and untagged UL35 have the ability to frequently form NBs in
transfected cells. In the context of CMV infection, UL35NBs have not been
detected (Liu and Biegalke, 2002), but this is not surprising given the
limited sensitivity of the only available UL35 antibody for NBs and the
interplay betweenUL35 andUL35a.UL35 is only present in the absence of
UL35a upon initial infection when it is delivered to the cell as a minor
tegument component (Varnum et al., 2004). At that time it might form
NBs, which would be expected to be small due to limited amounts of
UL35, and these might not be detected by the UL35 antiserum due to its
limited ability to stain NBs. Later in infection when UL35 is expressed
along with UL35a, detection of any potential UL35 NBs is further
complicated by the cross-reactivity of the UL35 antiserum with the
pan-nuclear UL35a. Therefore, whether or not UL35 forms NB in the
context of CMV infection remains an open question that requires new
UL35/UL35a antibodies or recombinant CMV with differently tagged
UL35/UL35a to resolve. Nonetheless, UL35 NB formation in transfected
Fig. 6. UL35a inhibits UL35 NB formation. (A) U2OS cells were transfected with UL35-F±control vector or UL35-F at a 1:9 ratio with UL35a-myc and, 24 h later, the effects on UL35 NB
formation were detected by immunoﬂuorescence using anti-FLAG and myc antibodies as indicated. (B) U2OS cells were transfected with UL35-F plasmid and an empty plasmid or with
UL35-F and UL35a-myc plasmids at 1:3 and 1:9 ratios as indicated. Cells were ﬁxed at 24 h post transfection and UL35 NBs were visualized by immunoﬂuorescence microscopy and
counted. The relative number of cellswithUL35NBs in the presence of increasing UL35awas determined for each individual experiment. Values represent themean±s.e. (n=3). (C) Cell
lysates for U2OS cells transfected as described for (B) were analyzed by Western blot for FLAG (UL35-F), myc (UL35a-myc) and actin levels as indicated. (D) A model for UL35
oligomerization anddisruptionbyUL35a.When expressed individually, UL35 can formhomotypicoligomers leading toNB formation (I).When co-expressed,UL35a can interactwith both
the N- and C-terminal regions of UL35, inhibiting formation of large UL35 complexes (II).
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and pp71 and for demonstrating interactions of PML and associated
proteins with UL35.
We and others observed that UL35 has the ability to associate with
PML NBs (Salsman et al., 2008; Schierling et al., 2004). Previous reports
noted that this PML-association was increased in the presence of pp71, a
viral tegument protein that interacts with UL35 (Schierling et al., 2004).
The results of this study, however, demonstrate that UL35 can form NBs
independently of PML and it is these NBs that ultimately recruit and
remodel PML bodies. In addition, we have shown that pp71 is not
required for UL35 NB formation and PML association. However, pp71
enhances the frequency andnumber ofUL35NBs in transfected cells, also
in a PML independent manner. Exactly how pp71 contributes to
increased UL35 NB formation is unclear. Despite the ability to interact,
we did not notice strong colocalization by immunoﬂuorescence between
UL35 NBs and pp71 suggesting that pp71might exert its effects on UL35
indirectly and independently of its ability to interactwithUL35. In light of
our recent ﬁndings, it is apparent that UL35 does not localize to
preexisting PML bodies but rather causes the recruitment and reorgani-
zation of PML. These UL35 NB-associated PML bodies contain Sp100 and
Daxx, two common PML body components, further suggesting that UL35
does not only redirect PML proteins but also PML-associated proteins.
We showed that UL35 and UL35a interact with each other and that,
whenpresent in excess, UL35a candisrupt theUL35 interactions that leadto NB formation. This effect is likely signiﬁcant late in infection when
UL35a levels canbe substantiallyhigher thanUL35 levels (Schierlinget al.,
2005). However, the ratio of UL35 to UL35a appears to be affected by the
MOI as another study, using a much higher MOI, found similar levels of
the two proteins (Liu and Biegalke, 2002), suggesting that differences in
infection conditions can alter the expression proﬁle of the UL35 gene. In
addition, the inhibitory effect of UL35a on UL35 NBsmay be relevant late
in infection when both proteins are expressed with pp71. Since pp71
promotes UL35 NB formation (Fig. 7, discussed below), UL35a may be
required to antagonize this activity and coordinate proper virion
assembly. In addition, the ability of UL35 to relocalize pp71 to cytoplasm
would also limit its ability to promote NB formation late in infection.
Ourdata on the formationand inhibitionofUL35NBspoint to amodel
in which UL35 NBs are the result of UL35 oligomerization which can be
prevented or disrupted by UL35a binding to UL35. Since UL35a is
comprisedof theC-terminal 193 aminoacids ofUL35, this sequencemust
be sufﬁcient for UL35 interactions. However, since UL35a fails to form
NBs and disrupts NB formation by UL35, UL35 sequences N-terminal to
this shared region must also be important for the interactions leading to
UL35 NBs. This hypothesis is supported by the observation that the UL35
N-terminal portion (amino acids 1–447) interacted with the UL35 C-
terminal (amino acids 448–640) region in co-immunoprecipitation
experiments. Therefore, NB formation by UL35 likely requires at least
twodifferent protein interaction domains, only one ofwhich is present in
Fig. 7.pp71enhancesUL35NB formation independentlyof PML. (A andB) Immunoﬂuorescence imagesofU2OS(A)orU2OS-shPMLcells (B) transfectedwithUL35-wt alone (left panel)or
UL35-wt and pp71-HA as indicated. Cells were immunostainedwith UL35 antiserum (UL35) or HA antibody (pp71) as indicated. Arrow in (A) indicates an example of UL35 and pp71 co-
localization. (C) Association of UL35 (red) and PML (green) in U2OS cells co-transfectedwith UL35-wt and pp71-HA. (D and E) Quantiﬁcation of the experiments in A and B showing the
average percentage of cells with UL35 NBs (D) and average number of UL35 NBs per cell (E). Values represent the mean±s.e. (n=3–5).
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where the N-terminal domain of one UL35 protein interacts with the C-
terminal domain of another UL35 protein, resulting in the formation of
largeUL35oligomers (Fig. 6D, part I). The interactionofUL35awith either
the N- or C-terminal portions of UL35 could inhibit this oligomerization
by acting as chain terminators (Fig. 6D, part II).
Experiments in which UL35 was co-expressed with pp71 showed
that pp71 enhances the efﬁciency of UL35 NB formation (Fig. 7),
which can recruit PML, but that this stimulation of UL35 NB formation
is independent of the presence of PML. Previous studies exploring the
connection between pp71, UL35 and PML also reported that pp71
could increase the efﬁciency of UL35 co-localization with PML bodies
(Schierling et al., 2005) and that this effect was consistent with the
ability of UL35 to cooperatively activate the MIEP with pp71. Our data
also show that pp71 increases the association of UL35 with PML, but
demonstrate that this is due to enhanced formation of UL35 NBs,
rather than enhanced association of UL35 with pre-existing PML
bodies. Nonetheless, it is possible that the same UL35-host protein
interaction(s) that leads to PML alteration might also contribute torelief of PML-mediated MIEP repression, even in the absence of UL35
NB formation.
Our studies on the interplay betweenUL35, UL35a and pp71 showed
that UL35a (but not UL35) caused pp71 to relocalize from the nucleus to
the cytoplasm (Fig. 8). This is interesting because, as CMV infection
proceeds, the localization of pp71 is known to change from nuclear to
cytoplasmic. In addition, deletion of the UL35 gene was previously
shown to cause pp71 to be retained in the nucleus throughout infection
(Schierling et al., 2005). Our results suggest that it is UL35a, and not
UL35, that is responsible for promoting the cytoplasmic localization of
pp71 during infection. In the same study using the UL35 deletion virus,
the tegument protein pp65 also failed to localize to the cytoplasm late in
infection, and the infection produced fewermature virions andnodense
bodies (Schierling et al., 2005). Thus, UL35 and/or UL35a are important
for proper virus assembly. It is unknown if the interaction between
UL35a and pp71 is required for the effects on localization, however, the
presence of cytoplasmic bodies that contain both UL35a and pp71
indicate that these two proteins can associate in the cytoplasm (Fig. 8).
There is also some indication that phosphorylation of pp71 contributes
Fig. 8.UL35a promotes the cytoplasmic accumulation of pp71. (A) Immunoﬂuorescence images of U2OS cells transfectedwith pp71-HA orUL35-wt as indicated and immunostainedwith
anti-HA (pp71) or UL35 antiserum (UL35a). DNAwas stained with DAPI (blue). (B) Quantiﬁcation of the subcellular localization of pp71-HA and UL35a from (A). The percentage of cells
with nuclear, pancellular or cytoplasmic localization is shown.Values represent themean±s.e. (n=4–5). (C) Immunoﬂuorescence images ofU2OS cells co-transfectedwith pp71-HAand
UL35-wt and immunostained with anti-HA (pp71) or UL35 antiserum (UL35a). DNA was stained with DAPI. Arrow indicates a cytoplasmic body. (D) Quantiﬁcation of the subcellular
localization of pp71-HA and UL35a when co-expressed as in (C). Values represent the mean±s.e. (n=3).
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of this modiﬁcation (Shen et al., 2008).
In summary,wehavedemonstrated thatUL35 formsNBs that recruit
PML, and that this effect is enhanced by pp71 and inhibited by UL35a.
The ability of UL35 NBs to recruit PML and associated proteins likely
reﬂects UL35-host protein interactions that can occur at various times in
infection and for various reasons. For example, the ability of UL35 from
the tegument, delivered to the cell upon infection, to associatewith PML
may be important in order for UL35 to be in close proximity to the viral
genomes, which are associated with PML NBs. In addition, the ability of
UL35 to remodel PML may be an indication of UL35's involvement in
cellular pathways that intersect with PML, such as transcriptional
regulation, apoptosis control and DNA repair, all of which are known to
be manipulated by herpesviruses to promote viral infection.
Materials and methods
Cells
U2OS human osteosarcoma and human embryonic kidney 293A cells
were maintained in DMEM supplemented with 10% FBS. Human
nasopharyngeal carcinoma cells CNE-2Z were maintained in α-MEM
supplemented with 10% FBS. U2OS cells with stable silencing of PML(shPML-U2OS)weregeneratedas follows. 293Tcellswere co-transfected
with the lentiviral plasmids pLKO.shPML1, pCMV.DR8.91 and pVSV-g
(kindly provided by Roger Everett; (Everett et al., 2006)) using
lipofectamine 2000 (Invitrogen) as per the manufacturer's instructions.
A total of 4 ml of culture supernatant containing lentiviral vector was
collected at 3 days post transfection followed by 0.45 μm ﬁltration to
avoid the carryover of 293T cells. Onemilliliter of lentiviral supernatant
was then added to 1×105 U2OS cells with polybrene (Sigma) at a ﬁnal
concentration of 8 μg/μl. The lentiviral supernatant was removed after
24 h and replaced with medium containing 0.4 μg/ml puromycin
(Bioshop) for 72 h. Puromycin-resistant U2OS cells with reduced PML
expression were then serial diluted in 96-well plates to obtain cultures
derived from individual cell colonies. Several colonieswere selected and
one with undetectable PML expression, as determined by immunoﬂu-
orescence and western blot, was maintained as described above for
U2OS cells.
Plasmids
The plasmid encodingUL35 (HCMV strain AD169)with a C-terminal
sequential peptide afﬁnity (SPA) tag (pUL35-S), composed of a
calmodulin binding peptide and a triple FLAG epitope, in the pMZS3F
vector (Zeghouf et al., 2004) was described previously (Salsman et al.,
128 J. Salsman et al. / Virology 414 (2011) 119–1292008). A plasmid encoding UL35 with a C-terminal triple FLAG epitope
tag (pUL35-F)was generated by subcloning theUL35 sequence from the
pMZS3F vector between the Xho1 and Xba1 sites of the pCMV-3FC
vector. To generate the pCMV-3FC vector, the triple FLAG portion of the
SPA tagwas PCR ampliﬁed andused to replace theYFP gene inpEYFPN1
(Invitrogen) by cloning between the Not1 and BamH1 restriction sites.
Untagged wild-type UL35 (pUL35-wt) was generated by inserting the
UL35 ORF with two stop codons before the C-terminal tag in pCMV-3FC
using the Xho1 and Xba1 restriction sites. UL35a with a SPA tag
(pUL35a-S), triple FLAG tag (pUL35a-F) and no tag (pUL35a-wt) were
generated using the respective UL35 constructs as templates to amplify
the UL35a sequence (amino acids 448–640). Myc-tagged UL35 (pUL35-
myc) andUL35a (pUL35a-myc) in the pCMV-3FCvectorwere generated
by PCR ampliﬁcation with primers designed to add a myc tag
(MEQKLISEEDL) and a stop codon to the C-terminus of the UL35 or
UL35a open reading frame and inserted between the Xho1 and Xba1
sites. pUL35N-F, consisting of the EBNA1 nuclear localization signal
(LKRPRSPSS, (Ambinder et al., 1991)) followed immediately by the N-
terminal portion of UL35 (amino acids 1–447), was ampliﬁed by PCR
and inserted between the Xho1 and Xba1 sites of pCMV-3FC. An HA-
tagged pp71 expression plasmid (pCGN71) was a gift from Tom Shenk
and has been previously described (Kalejta et al., 2003).
Primary antibodies
Rabbit serum raised against UL35 was a gift from Bonita Biegalke
(Liu and Biegalke, 2002). Mouse anti-FLAG (M2 clone), mouse anti-
PML and rabbit anti-Daxx were from Sigma-Aldrich. Rabbit anti-FLAG
and rabbit anti-PML were from Bethyl Laboratories. Rabbit anti-myc
was from AbCam. Rabbit anti-Sp100, anti-HA (rabbit and mouse) and
mouse anti-PML were from Santa Cruz Biotechnology. Rabbit antisera
against EBP2 is described in Wu et al. (2000).
Immunoﬂuorescence
Cells were seeded into 6-well plates on glass coverslips (~700,000
cells per well) and transfected with expression plasmids using
Lipofectamine 2000 (Invitrogen) as per the manufacturer's instructions,
using a DNA to Lipofectamine 2000 ratio of 2 μg:2 μl for 293A cells and
2 μg:4 μl for U2OS and CNE2Z cells. Transfected cells were ﬁxed ~40 h
post transfection (or at the indicated times) with 3.7% formaldehyde in
PBS (20 min), permeabilized with 0.5% Triton X-100 in PBS (10 min),
and blocked with 4% BSA in PBS (20 min) prior to incubation with
primary (1 h) and secondary (45 min) antibodies in 4% BSA in PBS.
Primary antibodies were detected using either goat anti-mouse or anti-
rabbit FAb fragments conjugated with Alexaﬂuor 488 or Alexaﬂuor 555
(Invitrogen). Coverslips were mounted onto slides using ProLong Gold
antifadeﬂuorescentmountingmedium (Invitrogen) containing DAPI for
visualization of nuclear DNA. Images were acquired using the 63× oil
objective (NA 1.4) on a Leica DM IRE2 inverted ﬂuorescent microscope.
Imageswere processed usingOpenLAB (ver.4.0.2) andAdobe Photoshop
version 6.0 using only linear adjustments.
Western blot
Cellswere lysed in cell lysis buffer (50 mMTris pH8.0, 150 mMNaCl,
1%NP-40) or in urea (50 mMTris pH 8.0, 9Murea) for detection of PML.
Cell lysates were sonicated if lysed in urea, cleared by centrifugation at
13,000g for 15 min at 4 °C and subjected to SDS–PAGE. Proteins were
transferred to nitrocellulose membranes, blocked with 4% milk and
incubated with the indicated primary antibodies (1 h) and goat anti-
mouse or goat anti-rabbit HRP-conjugated secondary antibodies
(45 min, Santa Cruz). Antibodies were detected by chemiluminescence
using Western Lighting chemiluminescent reagent (PerkinElmer) and
exposure to photographic ﬁlm (Amersham).Co-immunoprecipitation
U2OS cells in 10 cm plates were co-transfected with the indicated
FLAG and/or myc tagged proteins. At 40 h post transfection, cells were
washed twice with PBS and harvested. Cell pellets were lysed with cell
lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40) plus protease
inhibitor cocktail (P8340, Sigma). Cell lysates were clariﬁed by
centrifugation at 13,000g for 15 min at 4 °C. The FLAG-tagged protein
was immunoprecipitated (1 mgof lysate at ~4 mg/ml) in cell lysis buffer
and incubated with anti-FLAG resin (1:20,000 dilution, Sigma) for 2 h at
4 °C, while rotating. Beads were washed four times for 10 min in lysis
buffer and protein was eluted with 50 μl of protein sample buffer (5%
SDS, 20 mM Tris pH 8, 10% DTT, 20% glycerol). Western blots were then
performedasdescribed above todetect recovery of FLAG taggedproteins
and associatedmyc-tagged proteins (anti-myc 1:4000 dilution, Abcam).
Quantiﬁcation of nuclear bodies and protein localization
Quantiﬁcation of UL35 nuclear bodies or PML bodies was conducted
in U2OS, U2OS-shPML and CNE-2Z cells prepared as described above for
immunoﬂuorescence microscopy. The percent of UL35-expressing cells
containing UL35 nuclear bodies was determined by observing 100
random UL35-expressing cells and scoring each for the presence of dot
and/or donut shapedUL35nuclear bodies. For co-transfections only cells
expressing both transfected proteins were recorded. Quantiﬁcation of
the average number of PML bodies per transfected cell was determined
by recording the number of PML bodies in each of 50–100 transfected
cells. For localization data, the localization was categorized as nuclear or
cytoplasmic if 70% or more of the signal intensity localized to either
compartment. Cellswere categorized as pancellular if the intensity of the
cytoplasmic and nuclear was about equal. For each condition, the
localization in 100 cells was recorded and for co-transfections, data was
collected only for cells that expressed both of the transfected proteins.
For all quantiﬁcation assays, experiments were reproduced 3–5 times as
indicated in the ﬁgure legends. Statistical analyses (Student's t-test)
were conducted using Microsoft Excel 2007 software.
Supplementarymaterials related to this article canbe foundonlineat
doi:10.1016/j.virol.2011.03.013.
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